Top Markets
#1 Bedrock Bedrock +24.46%
#2 iExec RLC iExec RLC +22.99%
#3 API3 API3 +21.64%
#4 CyberDEX CyberDEX +19.33%
#5 Radicle Radicle +19.03%
#6 Talus Network Talus Network +18.92%
#7 The Bitcoin Bull The Bitcoin Bull +16.86%
#8 Orca Orca +13.08%
#9 VeThor VeThor +12.76%
#10 Nockchain Nockchain +11.65%
Coin of the day
Bedrock Bedrock
설정
언어
한국어
통화
USD
테마
Cell Source, Inc. Cell Source, Inc.

Cell Source, Inc.

CLCS
주식 순위 #28207
Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based... Cell Source, Inc. is a biotechnology firm dedicated to creating cell-based therapies centered on regulating immune tolerance. The company's flagship innovation is its Veto Cell immune system management technology, an advanced immune tolerance platform capable of selectively suppressing specific immune responses. This Veto Cell technology finds application in numerous areas, including enhancing the acceptance of stem cell transplants for conditions like lymphoma, leukemia, and multiple myeloma. Furthermore, it is utilized in treating end-stage kidney disease, various other non-malignant organ diseases, and a spectrum of both cancerous and non-malignant illnesses. Founded in 2012, Cell Source, Inc. maintains its corporate headquarters in New York, New York.
주가
$0.4
마지막 동기화: 2026-10-02
시가총액
$27.18M
변동 (1일)
-14.88%
변동 (1년)
8.11%
국가
US
거래 Cell Source, Inc. (CLCS)

카테고리

Healthcare
Cell Source, Inc. (CLCS)의 EPS
2026 기준 EPS TTM: 0
Cell Source, Inc.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
Cell Source, Inc.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $17.32 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $-7.98 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $-5.29 -
AU
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $27.74 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH